Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:mestranol
gptkb:norethynodrel |
| gptkbp:alsoKnownAs |
gptkb:Enovid-E
|
| gptkbp:approvalYear |
1960
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
gptkb:G03AA05
|
| gptkbp:category |
gptkb:oral_contraceptive
|
| gptkbp:countryOfOrigin |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:G._D._Searle_&_Company
|
| gptkbp:firstOralContraceptive |
true
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:historicalSignificance |
pioneered hormonal contraception
|
| gptkbp:legalStatus |
withdrawn
|
| gptkbp:marketedAs |
1957
|
| gptkbp:notableFor |
first birth control pill approved for contraceptive use
|
| gptkbp:purpose |
treatment of menstrual disorders
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache weight gain thromboembolism |
| gptkbp:usedAs |
gptkb:oral_contraceptive
|
| gptkbp:withdrawn |
1988
|
| gptkbp:bfsParent |
gptkb:G.D._Searle_&_Company
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enovid
|